Literature DB >> 12858217

A review on radiogenic Lhermitte's sign.

Olga Esik1, Tibor Csere, Klára Stefanits, Zsolt Lengyel, Géza Sáfrány, Katalin Vönöczky, Erzsébet Lengyel, Csaba Nemeskéri, Imre Repa, Lajos Trón.   

Abstract

Radiation myelopathy is a rare, but extremely serious side-effect of radiotherapy. Recovery from radiation-induced motor sequelae is rare, whereas, the regeneration of sensory losses is relatively frequent. Among the sensory radiogenic injuries of the spinal cord, Lhermitte's sign (LS) is most frequent. This review describes the clinical picture and diagnostic imaging signs of radiogenic LS. There have been only a few studies on large patient groups with radiogenic LS, demonstrating a rate of occurrence of 3.6-13%, relating mainly to mantle irradiation or the radiotherapy of head and neck tumors. These cases typically manifest themselves 3 months following radiotherapy and gradually disappear within 6 months. Only 3 LS cases have been described in the English literature with extraordinarily severe symptoms lasting for more than 1 year. MRI, a sensitive tool in the detection of demyelination, failed to reveal any pathological sign accompanying radiogenic LS. However, positron emission tomography demonstrated increased [18F]fluorodeoxyglucose accumulation and [15O]butanol perfusion, but a negligible [11C]methionine uptake in the irradiated spinal cord segments in patients with long-standing LS. These imaging data are suggestive of a close direct relationship between the regional perfusion and metabolism of the spinal cord, very much like the situation in the brain. We postulate that an altered, energy-demanding conduction along the demyelinated axons of patients with chronic radiogenic LS may explain the increased metabolism and perfusion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858217     DOI: 10.1007/bf03033755

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  65 in total

Review 1.  Radiation myelopathy with partial functional recovery: PET evidence of long-term increased metabolic activity of the spinal cord.

Authors:  O Esik; M Emri; M Csornai; M Kásler; M Gödény; L Trón
Journal:  J Neurol Sci       Date:  1999-02-01       Impact factor: 3.181

2.  Demyelinating diseases--new pathological insights, new therapeutic targets.

Authors:  S G Waxman
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

3.  Lhermitte's sign following chemotherapy with docetaxel.

Authors:  M J van den Bent; P H Hilkens; P A Sillevis Smitt; V J van Raaij-van den Aarssen; M Bontenbal; J Verweij
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

4.  Conduction in segmentally demyelinated mammalian central axons.

Authors:  P A Felts; T A Baker; K J Smith
Journal:  J Neurosci       Date:  1997-10-01       Impact factor: 6.167

5.  Delayed radiation myelopathy in man. Report of twelve necropsy cases.

Authors:  K Jellinger; K W Sturm
Journal:  J Neurol Sci       Date:  1971-12       Impact factor: 3.181

6.  Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation.

Authors:  J A Word; U P Kalokhe; B S Aron; H R Elson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-12       Impact factor: 7.038

7.  Development of Lhermitte's sign after bone marrow transplantation.

Authors:  P Y Wen; K L Blanchard; C C Block; J S Loeffler; D G Davis; L A Lacroix; J H Antin
Journal:  Cancer       Date:  1992-05-01       Impact factor: 6.860

8.  Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease.

Authors:  O Lang; H Bihl; B Hültenschmidt; M L Sautter-Bihl
Journal:  Strahlenther Onkol       Date:  2001-03       Impact factor: 3.621

Review 9.  Radiation response of the central nervous system.

Authors:  T E Schultheiss; L E Kun; K K Ang; L C Stephens
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

10.  Fibroblast radiosensitivity versus acute and late normal skin responses in patients treated for breast cancer.

Authors:  W A Brock; S L Tucker; F B Geara; I Turesson; J Wike; J Nyman; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

View more
  8 in total

1.  Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms.

Authors:  Daniel Pak; Karen Vineberg; Felix Feng; Randall K Ten Haken; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-26       Impact factor: 7.038

2.  Treatment related myelitis in Hodgkin's lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature.

Authors:  Heather Gatcombe; Josh Lawson; Surasak Phuphanich; Ian Crocker
Journal:  J Neurooncol       Date:  2006-04-15       Impact factor: 4.130

3.  Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer.

Authors:  V E M Mul; J M A de Jong; L H P Murrer; P L A van den Ende; R M A Houben; M Lacko; P Lambin; B G Baumert
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

Review 4.  Manifestations of radiation toxicity in the head, neck, and spine: An image-based review.

Authors:  Carrie M Carr; John C Benson; David R DeLone; Felix E Diehn; Dong K Kim; Daniel Ma; Alex A Nagelschneider; Ajay A Madhavan; Derek R Johnson
Journal:  Neuroradiol J       Date:  2022-05-01

Review 5.  Head and neck cancer survivorship consensus statement from the American Head and Neck Society.

Authors:  Neerav Goyal; Andrew Day; Joel Epstein; Joseph Goodman; Evan Graboyes; Scharukh Jalisi; Ana P Kiess; Jamie A Ku; Matthew C Miller; Aru Panwar; Vijay A Patel; Assuntina Sacco; Vlad Sandulache; Amy M Williams; Daniel Deschler; D Gregory Farwell; Cherie-Ann Nathan; Carole Fakhry; Nishant Agrawal
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-11-30

6.  Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma.

Authors:  Bassem Youssef; JoAnn Shank; Jay P Reddy; Chelsea C Pinnix; George Farha; Mani Akhtari; Pamela K Allen; Michelle A Fanale; John A Garcia; Patricia H Horace; Sarah Milgrom; Grace Li Smith; Yago Nieto; Isadora Arzu; He Wang; Nathan Fowler; Maria Alma Rodriguez; Bouthaina Dabaja
Journal:  Radiat Oncol       Date:  2015-09-25       Impact factor: 3.481

7.  Lhermitte's Sign following VMAT-Based Head and Neck Radiation-Insights into Mechanism.

Authors:  Huaising C Ko; Allison R Powers; Ren-dih Sheu; Sarah L Kerns; Barry S Rosenstein; Stephen C Krieger; Waleed F Mourad; Kenneth S Hu; Vishal Gupta; Richard L Bakst
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

8.  Identifying risk factors for L'Hermitte's sign after IMRT for head and neck cancer.

Authors:  Hannah M Laidley; David J Noble; Gill C Barnett; Julia R Forman; Amy M Bates; Richard J Benson; Sarah J Jefferies; Rajesh Jena; Neil G Burnet
Journal:  Radiat Oncol       Date:  2018-05-04       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.